Sight Sciences/$SGHT
1D1W1MYTD1Y5YMAX
Capital at risk
About Sight Sciences
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
- Ticker
- $SGHT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 186
- Headquarters
- Menlo Park, United States
- Website
- www.sightsciences.com
Sight Sciences Metrics
BasicAdvanced
$448M
-
-$0.56
2.42
-
Price and volume
Market cap
$448M
Beta
2.42
52-week high
$9.24
52-week low
$3.19
Average daily volume
267K
Financial strength
Current ratio
4.949
Quick ratio
4.446
Long term debt to equity
59.457
Total debt to equity
79.355
Interest coverage (TTM)
-3.82%
Profitability
EBITDA (TTM)
-19.264
Gross margin (TTM)
87.96%
Net profit margin (TTM)
-35.69%
Operating margin (TTM)
-23.60%
Effective tax rate (TTM)
0.10%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
-10.84%
Return on equity (TTM)
-48.42%
Valuation
Price to revenue (TTM)
5.221
Price to book
8.42
Price to tangible book (TTM)
8.42
Price to free cash flow (TTM)
-18.66
Free cash flow yield (TTM)
-5.36%
Free cash flow per share (TTM)
-0.436
Growth
Revenue change (TTM)
9.27%
Earnings per share change (TTM)
-42.02%
3-year revenue growth (CAGR)
0.76%
3-year earnings per share growth (CAGR)
-27.67%
What the Analysts think about Sight Sciences
Analyst ratings (Buy, Hold, Sell) for Sight Sciences stock.
Analyst projections of the future price of Sight Sciences stock.
Bulls say / Bears say
Second quarter 2026 revenue grew 19.6% year-on-year to $23.4 million, driven by contributions from both Interventional Glaucoma and Dry Eye segments. (GlobeNewswire) (Reuters)
Record Interventional Dry Eye revenue of $2.7 million in Q2, a 703% increase year-on-year, reflecting successful reimbursement progress and expanding procedural adoption. (GlobeNewswire)
Management raised full-year 2026 revenue guidance to $88 million–$92 million from $83 million–$89 million, signaling confidence in sustained top-line momentum. (GlobeNewswire)
The company reported a net loss of $4.4 million in Q2 2026, underscoring ongoing unprofitability despite improved revenue. (GlobeNewswire)
Interventional Glaucoma revenue grew only 7.7% year-on-year to $20.7 million in Q2, indicating modest adoption of its core surgical device portfolio. (SEC 10-Q)
Final judgment awarding $55.4 million in past damages and ongoing royalties from Alcon is subject to appeal and ex parte reexamination proceedings, risking delays or reductions in expected cash inflows. (SEC 8-K)
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2026.
Sight Sciences Financial Performance
Revenues and expenses
Sight Sciences Earnings Performance
Company profitability
Upcoming events
No upcoming events
Sight Sciences News
AllArticlesVideos
Funds containing Sight Sciences
Fund name | Fund size | $SGHT weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.